Selection and analysis of anti-cancer antibodies for cancer therapy obtained from antibody phage library

Cancer Science

Volumn 102, Issue 1, 2011, Pages 175-181

  Kurosawa, Gene ^a   Sumitomo, Mariko ^a   Ukai, Yoshinori ^b   Subere, Juvy ^a   Muramatsu, Chiho ^a   Eguchi, Keiko ^a   Tanaka Hashiba, Miho ^a   Sugiura, Mai ^b   Ando, Misaki ^a   Sato, Noriko ^c   Morita, Miwa ^c   Inaba, Kazuki ^c   Morigaki, Satoko ^c   Takasaki, Akihiko ^d   Akahori, Yasushi ^a   Miyakawa, Shuichi ^c   Uyama, Ichiro ^c   Maeda, Koutarou ^c   Shiroki, Ryoichi ^c   Hoshinaga, Kiyotaka ^c   Mizoguchi, Yoshikazu ^c   Hattori, Yoshinobu ^c   Sugioka, Atsushi ^c   Sugiura, Mototaka ^c   Kurosawa, Yoshikazu ^a   more..

^a FUJITA HEALTH UNIVERSITY   (Japan)

^b Institute for Antibodies CO LTD   (Japan)

^c FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d GIFU UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER ANTIBODY; CD9 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; INTERCELLULAR ADHESION MOLECULE 1; TUMOR ANTIGEN;

ANTIBODY LIBRARY; ARTICLE; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER THERAPY; CARCINOGENESIS; CELL STRAIN CACO 2; CELL STRAIN HEPG2; CELL STRAIN HT29; CELL STRAIN LNCAP; CELL STRAIN MCF 7; COLON CARCINOMA; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; LUNG CARCINOMA; MELANOMA; OUTCOME ASSESSMENT; OVARY CARCINOMA; PANCREAS CARCINOMA; PHAGE DISPLAY; PRIORITY JOURNAL; PROSTATE CARCINOMA; STOMACH CANCER; STOMACH CARCINOMA;

ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, NEOPLASM; CELL PROLIFERATION; HUMANS; IMMUNOHISTOCHEMISTRY; PEPTIDE LIBRARY;

EID: 78650209114     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01739.x     Document Type: Article

References (25)

1. HER2 antibody for human cancer therapy. Proc Natl Acad Sci USA 1992; 89: 4285-9.
2. Reff ME, Carner K, Chambers KS et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435-45.
3. Reichert JM, Valge-Archer VE. Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov 2007; 6: 349-56.
4. Kurosawa G, Akahori Y, Morita M et al. Comprehensive screening for antigens overexpressed on carcinomas via isolation of human mAbs that may be therapeutic. Proc Natl Acad Sci USA 2008; 105: 7287-92.
5. Akahori Y, Kurosawa G, Sumitomo M et al. Isolation of antigen/antibody complexes through organic solvent (ICOS) method. Biochem Biophys Res Commun 2009; 378: 832-5.
6. Kurosawa G, Sumitomo M, Akahori Y et al. Methods for comprehensive identification of membrane proteins recognized by a large number of monoclonal antibodies. J Immunol Methods 2009; 351: 1-12.
7. Goldstein NI, Prewett M, Zuklys K, Rockwell P, Mendelsohn J. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res 1995; 1: 1311-8.
8. Presta LG, Chen H, O'Connor SJ et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997; 57: 4593-9.
9. Carter P, Smith L, Ryan M. Identification and validation of cell surface antigens for antibody targeting in oncology. Endocr Relat Cancer 2004; 11: 659-87.
10. Clynes RA, Towers TL, Presta LG, Ravetch JV. Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets. Nat Med 2000; 6: 443-6.
11. Gaetano ND, Cittera E, Nota R et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol 2003; 171: 1581-7.
12. Grunwald V, Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst 2003; 95: 851-67.
13. Hynes NE, Lane HA. ErbB receptors and cancer: the complexity of the targeted inhibitors. Nat Rev Cancer 2005; 5: 341-54.
14. Rocha-Lima CM, Soares HP, Raez LE, Singal R. EGFR targeting of solid tumors. Cancer Control 2007; 14: 295-304.
15. Morino K, Katsumi H, Akahori Y et al. Antibody fusions with fluorescent proteins: a versatile reagent for profiling protein expression. J Immunol Methods 2001; 257: 175-84.
16. Kitamura Y, Kurosawa G, Tanaka M et al. Frequent overexpression of CADM1/IGSF4 in lung adenocarcinoma. Biochem Biophys Res Commun 2009; 383: 480-4.
17. Scudiero DA, Shoemaker RH, Paull KD et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 1988; 48: 4827-33.
18. Lo HW, Hsu SC, Hung MC. EGFR signaling pathway in breast cancers: from traditional signal transduction to direct nuclear translocation. Breast Cancer Res Treat 2006; 95: 211-8.
19. Uekita T, Jia L, Narisawa-Saito M, Yokota J, Kiyono T, Sakai R. CUB domain-containing protein 1 is a novel regulator of anoikis resistance in lung adenocarcinoma. Mol Cell Biol 2007; 27: 7649-60.
20. Siva AC, Wild MA, Kirkland RE et al. Targeting CUB domain-containing protein 1 with a monoclonal antibody inhibits metastasis in a prostate cancer model. Cancer Res 2008; 68: 3759-66.
21. Vogel W, Lammers R, Huang J, Ullrich A. Activation of a phosphotyrosine phosphatase by tyrosine phosphorylation. Science 1993; 259: 1611-4.
22. Zhi X, Chen S, Zhou P et al. RNA interference of ecto-5'-nucleotidase (CD73) inhibits human breast cancer cell growth and invasion. Clin Exp Metastasis 2007; 24: 439-48.
23. Schmidt DS, Klingbeil P, Schnoelzer M, Zoeller M. CD44 variant isoforms associate with tetraspanins and EpCAM. Exp Cell Res 2004; 297: 329-47.
24. Claas C, Wahl J, Orlicky DJ et al. The tetraspanin D6.1A and its molecular partners on rat carcinoma cells. Biochem J 2005; 389: 99-110.
25. Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signaling regulators. Nat Rev Mol Cell Biol 2003; 4: 33-45.